SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-19T14:16:02.066097+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:bee786ac0447a244","evidence_event_ids":["evt_d95989cc10c1"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-dnth-cfo-sold-8224-shares-739000","as_of":"2026-04-19T14:16:02.066097+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/19/dianthus-therapeutics-dnth-cfo-sold-8-224-shares-for-usd739-000/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-dnth-cfo-sold-8224-shares-739000","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_8c15c73643aa07c2","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/19/dianthus-therapeutics-dnth-cfo-sold-8-224-shares-for-usd739-000/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-19T14:45:46.666350+00:00","extraction_method":"trafilatura","fetched_description":"Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share.","fetched_title":"Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 | Nasdaq","final_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-dnth-cfo-sold-8224-shares-739000","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/dianthus-therapeutics-dnth-cfo-sold-8224-shares-739000","source_event_id":"evt_d95989cc10c1","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"b96438a48cfe0b2a","kind":"unusual_volume","published_at":"2026-04-19T13:28:22+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 9, 2026","December 2025","March 9, 2026","March 12, 2026","April 17, 2026"],"entities":[{"asset_class":"equity","name":"Dianthus Therapeutics","relevance":"high","symbol":"DNTH","type":"company"},{"asset_class":"equity","name":"Ryan Savitz","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"Motley Fool","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"other","information_gaps":["No unusual volume delta metrics are provided (baseline volume, volume ratio, or direction are not stated).","The catalyst hypothesis for \u201cunusual volume\u201d cannot be determined from the text because the signal\u2019s volume information is not included.","No confirmation from independent news sources is provided beyond the SEC Form 4 disclosure as described in the article.","analysis_basis_note_for_unusual_volume_delta_catalyst_hypothesis_needed_if_available:","The article discusses insider selling structure (Rule 10b5-1) and prior clinical/financing context, but does not quantify or confirm any volume spike relative to average."],"key_facts":["Ryan Savitz (DNTH CFO) sold 8,224 shares of common stock on April 9, 2026.","Total proceeds were approximately $739,000.","The weighted-average price was around $89.84 per share (per SEC Form 4 disclosure).","The transaction represented 100% of Savitz\u2019s direct common stock holdings, reducing his direct and indirect ownership in this class to zero shares.","The transaction was structured as an option exercise and immediate sale.","The filing indicates the transaction involved only direct holdings (no participation by trusts or other entities).","Savitz retained 71,776 stock options that could be converted into common stock in the future.","The sale was executed under a Rule 10b5-1 plan adopted in December 2025.","The article characterizes the activity as consistent with pre-scheduled, routine liquidity management rather than a discretionary strategic change."],"numeric_claims":[{"label":"shares_sold","value":"8,224"},{"label":"proceeds_usd","value":"~739,000"},{"label":"weighted_avg_price_usd","value":"~89.84"},{"label":"direct_shares_after","value":"0"},{"label":"stock_options_retained","value":"71,776"}],"primary_claim":"On April 9, 2026, DNTH CFO Ryan Savitz sold 8,224 shares for approximately $739,000 at a weighted-average price of about $89.84 per share under a Rule 10b5-1 plan.","relevance_score":0.42,"sentiment":"neutral","source_quality":"high","summary":"Dianthus Therapeutics (DNTH) CFO Ryan Savitz sold 8,224 shares of common stock on April 9, 2026 for about $739,000 after exercising options at a weighted-average price of ~$89.84. The sale was executed as an option exercise and immediate sale under a Rule 10b5-1 plan adopted in December 2025, leaving him with 71,776 stock options but zero direct shares.","topics":["insider trading","SEC Form 4","Rule 10b5-1 plan","stock option exercise","executive compensation","clinical-stage biotech"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share.","tickers":["DNTH"],"title":"Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000","url":"https://www.fool.com/coverage/filings/2026/04/19/dianthus-therapeutics-dnth-cfo-sold-8-224-shares-for-usd739-000/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 314408 in events